BMS-204352 (Bristol Myers Squibb).
BMS-204352 is a fluoro-oxindole potassium channel opener being developed by Bristol-Myers Squibb as a potential neuroprotectant for the treatment of acute ischemic stroke. Phase I trials were underway in Japan in 1998 [288541]. By July 1999, it was in phase II trials in the US [331682] and by October 2000, phase II trials had also begun in Japan [384751]. At the 219th American Chemical Society meeting in March 2000, it was reported that BMS-204352 had entered worldwide phase III trials involving patients with suspected acute stroke [362077], [361291]. In February 2001, Credit Suisse First Boston predicted sales of $111 million in 2005 [399484]. In February 1999, Lehman Brothers predicted the drug had a 30% probability of reaching market, with an estimated first launch date in 2004. The analysts predicted peak sales would occur in 2008, with sales of $500 million in the US at that time [319225].
Mackay
K B
KB
Neurocrine Biosciences Inc, Department of Neuroscience, San Diego, CA 92121-1102, USA. kmackay@neurocrine.com
D000208:Acute Disease; D000818:Animals; D002986:Clinical Trials as Topic; D000075202:Contraindications; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D020521:Stroke / Q000188:drug therapy* / Q000523:psychology; D013329:Structure-Activity Relationship
C424388:BMS204352; D007211:Indoles; D018696:Neuroprotective Agents